Dorsey & Whitney Trust CO LLC Acquires 47,228 Shares of Neuronetics, Inc. (NASDAQ:STIM)

Dorsey & Whitney Trust CO LLC raised its holdings in Neuronetics, Inc. (NASDAQ:STIM) by 97.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 95,880 shares of the company’s stock after buying an additional 47,228 shares during the period. Dorsey & Whitney Trust CO LLC owned about 0.32% of Neuronetics worth $173,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Worth Venture Partners LLC purchased a new stake in shares of Neuronetics in the fourth quarter valued at about $30,000. Millrace Asset Group Inc. raised its holdings in shares of Neuronetics by 205.1% in the fourth quarter. Millrace Asset Group Inc. now owns 725,369 shares of the company’s stock valued at $2,104,000 after purchasing an additional 487,591 shares during the last quarter. G2 Investment Partners Management LLC purchased a new stake in shares of Neuronetics in the fourth quarter valued at about $213,000. SG Americas Securities LLC purchased a new stake in shares of Neuronetics in the first quarter valued at about $62,000. Finally, Silvercrest Asset Management Group LLC raised its holdings in shares of Neuronetics by 4.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 1,178,365 shares of the company’s stock valued at $5,609,000 after purchasing an additional 51,881 shares during the last quarter. 53.59% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

STIM has been the subject of a number of research analyst reports. JMP Securities decreased their price objective on shares of Neuronetics from $7.00 to $3.00 and set a “market outperform” rating for the company in a report on Wednesday, August 14th. Canaccord Genuity Group decreased their price objective on shares of Neuronetics from $6.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. Finally, William Blair restated a “market perform” rating on shares of Neuronetics in a report on Monday, August 12th.

Insider Activity

In related news, Director Robert Cascella bought 35,000 shares of the company’s stock in a transaction on Wednesday, August 14th. The stock was acquired at an average cost of $0.79 per share, for a total transaction of $27,650.00. Following the completion of the transaction, the director now directly owns 279,098 shares in the company, valued at approximately $220,487.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Neuronetics news, CEO Keith J. Sullivan sold 24,162 shares of Neuronetics stock in a transaction that occurred on Thursday, July 18th. The shares were sold at an average price of $1.90, for a total transaction of $45,907.80. Following the transaction, the chief executive officer now directly owns 1,324,354 shares of the company’s stock, valued at $2,516,272.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert Cascella purchased 35,000 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were acquired at an average cost of $0.79 per share, for a total transaction of $27,650.00. Following the completion of the purchase, the director now directly owns 279,098 shares of the company’s stock, valued at approximately $220,487.42. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 111,776 shares of company stock worth $100,170. 9.80% of the stock is owned by company insiders.

Neuronetics Price Performance

STIM opened at $0.74 on Friday. The company has a market capitalization of $22.42 million, a price-to-earnings ratio of -0.77 and a beta of 2.28. The company has a quick ratio of 2.37, a current ratio of 2.58 and a debt-to-equity ratio of 2.38. The firm has a 50-day moving average price of $1.39 and a 200-day moving average price of $2.51. Neuronetics, Inc. has a twelve month low of $0.66 and a twelve month high of $5.07.

Neuronetics (NASDAQ:STIM) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). Neuronetics had a negative net margin of 45.06% and a negative return on equity of 109.00%. The firm had revenue of $16.45 million during the quarter, compared to the consensus estimate of $18.76 million. During the same quarter last year, the business posted ($0.17) earnings per share. Equities analysts expect that Neuronetics, Inc. will post -0.87 EPS for the current year.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.